Retatrutide is currently the most-searched research peptide in Europe. German, Dutch, French, and Belgian researchers are discovering the compound’s published Phase II data and looking for a reliable source. What many encounter first is a UK-based supplier — and then the question arises: can I import this from the UK without customs problems?
This article answers that question directly and explains why an EU warehouse matters more than ever in 2026.
Why European Researchers Are Searching for Retatrutide
Retatrutide (LY3437943) demonstrated the highest weight reduction signal of any compound tested in a randomised trial to date. The Phase II data published in the New England Journal of Medicine (Jastreboff et al., 2023) showed a mean -24.2% body weight reduction at the 12 mg dose over 48 weeks.
This efficacy signal — superior to semaglutide (-15%) and tirzepatide (-22%) in comparative context — has driven rapid growth in researcher interest across all European markets. Search data confirms this: retatrutide-related queries have grown over 1,000% year-on-year across Germany, the Netherlands, and France.
The UK-to-Europe Customs Problem
Most retatrutide available online is shipped from the UK. Since Brexit, UK-to-EU shipments are classified as imports from a third country. This has practical consequences:
What happens at the EU border
- Customs declaration required — all commercial shipments from the UK must clear EU customs
- Product classification matters — research peptides may be assessed under Chapter 29 (organic chemicals) or Chapter 30 (pharmaceutical products), both of which attract customs officer attention
- Seizure risk is real — EU customs authorities have increased scrutiny of chemical imports from the UK since 2021
- Delays are common — even cleared shipments may sit in customs for 2–4 weeks
What “EU warehouse” actually means
When a supplier ships from within the EU:
- No customs declaration between EU member states
- No third-country import classification
- Delivery treated the same as any domestic parcel
- Transit times are 3–5 days with tracking
The distinction is not cosmetic. It determines whether your research order arrives in a week or sits in a customs facility indefinitely.
Retatrutide: What European Researchers Need to Know
Mechanism of action
Retatrutide is a triple GLP-1/GIP/glucagon receptor agonist. The glucagon receptor component — absent in semaglutide and tirzepatide — adds two mechanistic effects:
- Hepatic fatty acid oxidation — the liver burns fat as fuel at a higher rate
- Thermogenesis — elevated resting energy expenditure
This is why the compound’s efficacy exceeds dual-agonist compounds in Phase II data.
Published evidence
| Compound | Receptor | Peak Phase II Weight Loss | Source |
|---|---|---|---|
| Semaglutide | GLP-1R | -15.3% | NEJM 2021 |
| Tirzepatide | GLP-1R + GIPR | -22.5% | NEJM 2022 |
| Retatrutide | GLP-1R + GIPR + GCGR | -24.2% | NEJM 2023 |
The Phase III TRIUMPH programme is currently ongoing across 45+ centres. Phase III results are anticipated from 2026.
Storage and reconstitution
- Lyophilised storage: -20°C, stable 18+ months
- Reconstitution solvent: Bac Water (0.9% benzyl alcohol)
- Reconstituted solution: 2–8°C, 28 days
Sourcing Retatrutide in Europe: Practical Checklist
When evaluating a European research peptide supplier:
- Confirm EU warehouse location — ask for a specific country, not just “Europe”
- Request purity documentation — minimum >99% analytical purity
- Check lot-specific COA availability — mass spectrometry + HPLC
- Verify discreet packaging — outer parcel should carry no identifying product information
- Confirm tracked delivery — every shipment should include a tracking number
Availability at UK Peptides
We stock retatrutide from an EU warehouse with 3–5 day tracked delivery across Germany, France, the Netherlands, Belgium, and all EU member states.
-
99% purity
- Bac Water included for reconstitution
- Available in 10 mg, 20 mg, and 30 mg formats
- No customs intervention — EU to EU
All products are Research Use Only. Not for human consumption. Retatrutide is not an approved medicine.